US4132746A
(en)
|
1976-07-09 |
1979-01-02 |
University Of Alabama, Birmingham Medical & Education Foundation |
Synthetic elastomeric insoluble cross-linked polypentapeptide
|
US4187852A
(en)
|
1976-07-09 |
1980-02-12 |
The University Of Alabama |
Synthetic elastomeric insoluble cross-linked polypentapeptide
|
US4500700A
(en)
|
1981-10-02 |
1985-02-19 |
The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham |
Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three
|
US4474851A
(en)
|
1981-10-02 |
1984-10-02 |
The University Of Alabama In Birmingham |
Elastomeric composite material comprising a polypeptide
|
US4589882A
(en)
|
1983-09-19 |
1986-05-20 |
Urry Dan W |
Enzymatically crosslinked bioelastomers
|
US4752638A
(en)
|
1983-11-10 |
1988-06-21 |
Genetic Systems Corporation |
Synthesis and use of polymers containing integral binding-pair members
|
US4749647A
(en)
|
1984-06-22 |
1988-06-07 |
Genetic Systems Corporation |
Polymerization-induced separation assay using recognition pairs
|
US4734400A
(en)
|
1984-10-09 |
1988-03-29 |
Hoffmann-La Roche Inc. |
Synthetic vasoactive intestinal peptide analogs
|
US4605641A
(en)
|
1984-10-09 |
1986-08-12 |
Hoffmann-La Roche Inc. |
Synthetic vasoactive intestinal peptide analogs
|
US4870055A
(en)
|
1986-04-17 |
1989-09-26 |
University Of Alabama At Birmingham |
Segmented polypeptide bioelastomers to modulate elastic modulus
|
US4783523A
(en)
|
1986-08-27 |
1988-11-08 |
Urry Dan W |
Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides
|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
US4898926A
(en)
|
1987-06-15 |
1990-02-06 |
The University Of Alabama At Birmingham/Research Foundation |
Bioelastomer containing tetra/penta-peptide units
|
US5496712A
(en)
|
1990-11-06 |
1996-03-05 |
Protein Polymer |
High molecular weight collagen-like protein polymers
|
US6184348B1
(en)
|
1986-11-04 |
2001-02-06 |
Protein Polymer Technologies |
Functional recombinantly prepared synthetic protein polymer
|
US5514581A
(en)
|
1986-11-04 |
1996-05-07 |
Protein Polymer Technologies, Inc. |
Functional recombinantly prepared synthetic protein polymer
|
US5641648A
(en)
|
1986-11-04 |
1997-06-24 |
Protein Polymer Technologies, Inc. |
Methods for preparing synthetic repetitive DNA
|
US5770697A
(en)
|
1986-11-04 |
1998-06-23 |
Protein Polymer Technologies, Inc. |
Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
|
US6018030A
(en)
|
1986-11-04 |
2000-01-25 |
Protein Polymer Technologies, Inc. |
Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
|
US5830713A
(en)
|
1986-11-04 |
1998-11-03 |
Protein Polymer Technologies, Inc. |
Methods for preparing synthetic repetitive DNA
|
US5773249A
(en)
|
1986-11-04 |
1998-06-30 |
Protein Polymer Technologies, Inc. |
High molecular weight collagen-like protein polymers
|
US5243038A
(en)
|
1986-11-04 |
1993-09-07 |
Protein Polymer Technologies, Inc. |
Construction of synthetic DNA and its use in large polypeptide synthesis
|
US4835252A
(en)
|
1987-02-26 |
1989-05-30 |
The Salk Institute Biotechnology/Industrial Associates, Inc. |
Vasoactive intestinal peptide analogs
|
US4939224A
(en)
|
1987-02-26 |
1990-07-03 |
The Salk Institute Biotechnology/Industrial Associates, Inc. |
Vasoactive intestinal peptide analogs
|
US5606019A
(en)
|
1987-10-29 |
1997-02-25 |
Protien Polymer Technologies, Inc. |
Synthetic protein as implantables
|
IL87055A
(en)
|
1988-07-08 |
1994-06-24 |
Illana Gozes |
Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
|
US5766883A
(en)
|
1989-04-29 |
1998-06-16 |
Delta Biotechnology Limited |
Polypeptides
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5141924A
(en)
|
1989-06-30 |
1992-08-25 |
Hoffmann-La Roche, Inc. |
Synthetic vasoactive intestinal peptide analogs
|
US5234907A
(en)
|
1989-06-30 |
1993-08-10 |
Hoffmann-La Roche Inc. |
Synthetic vasoactive intestinal peptide analogs
|
US5447912A
(en)
|
1989-09-18 |
1995-09-05 |
Senetek, Plc |
Erection-inducing methods and compositions
|
US5236904A
(en)
|
1989-09-18 |
1993-08-17 |
Senetek, Plc |
Erection-inducing methods and compositions
|
EP0449592B1
(en)
|
1990-03-27 |
1994-11-30 |
Bioelastics Research, Ltd. |
Bioelastomeric drug delivery system
|
EP0463450B1
(en)
|
1990-06-26 |
1994-02-16 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Vasoactive intestinal polypeptide analogues and use thereof
|
JPH07108232B2
(ja)
|
1990-10-09 |
1995-11-22 |
エム・ディ・リサーチ株式会社 |
ペプチド又は蛋白質の製造方法
|
US5235041A
(en)
|
1990-12-28 |
1993-08-10 |
Protein Polymer Technologies, Inc. |
Purification of structurally ordered recombinant protein polymers
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5393602A
(en)
|
1991-04-19 |
1995-02-28 |
Bioelastics Research Ltd. |
Superabsorbent materials and uses thereof
|
JPH05238950A
(ja)
|
1991-04-22 |
1993-09-17 |
Sanwa Kagaku Kenkyusho Co Ltd |
易吸収性vip製剤
|
US5958881A
(en)
|
1991-04-25 |
1999-09-28 |
Korman; Louis Y. |
Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
|
AU656230B2
(en)
|
1991-10-11 |
1995-01-27 |
F. Hoffmann-La Roche Ag |
Cyclic vasoactive peptides
|
US5681816A
(en)
|
1992-04-24 |
1997-10-28 |
Korman; Louis Y. |
Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
|
US5288514A
(en)
|
1992-09-14 |
1994-02-22 |
The Regents Of The University Of California |
Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
|
US5972883A
(en)
|
1993-03-16 |
1999-10-26 |
Yeda Research And Development Co. Ltd. |
Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
|
US5545617A
(en)
|
1993-11-12 |
1996-08-13 |
The Schepens Eye Research Institute, Inc. |
Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5900405A
(en)
|
1994-01-24 |
1999-05-04 |
Bioelastics Research, Ltd. |
Polymers responsive to electrical energy
|
CA2187322A1
(en)
|
1994-04-07 |
1995-10-19 |
Israel Rubinstein |
Vasoactive intestinal polypeptide
|
US5527610A
(en)
|
1994-05-20 |
1996-06-18 |
The Uab Research Foundation |
Elastomeric polypeptide matrices for preventing adhesion of biological materials
|
US6004782A
(en)
|
1995-04-14 |
1999-12-21 |
Bioelastics Research Ltd. |
Hyperexpression of bioelastic polypeptides
|
US5972406A
(en)
|
1995-04-14 |
1999-10-26 |
Bioelastics Research Ltd. |
Bioelastomers suitable as food product additives
|
US5854387A
(en)
|
1995-04-14 |
1998-12-29 |
Bioelastics Research, Ltd. |
Simple method for the purification of a bioelastic polymer
|
US5624711A
(en)
|
1995-04-27 |
1997-04-29 |
Affymax Technologies, N.V. |
Derivatization of solid supports and methods for oligomer synthesis
|
US6037321A
(en)
|
1995-05-03 |
2000-03-14 |
Biostar Inc. |
Fusion proteins comprising vasoactive intestinal peptide or PACAP
|
EP0851768B1
(en)
|
1995-09-01 |
2002-04-24 |
University of Washington |
Interactive molecular conjugates
|
US5702717A
(en)
|
1995-10-25 |
1997-12-30 |
Macromed, Inc. |
Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
|
HU230515B1
(hu)
|
1996-02-09 |
2016-10-28 |
Abbvie Biotechnology Ltd |
Humán TNFalfa-kötő antitestek alkalmazásai
|
JP2000504676A
(ja)
|
1996-02-09 |
2000-04-18 |
エフ・ホフマン―ラ ロシュ アーゲー |
Vipアナログの合成
|
US6063061A
(en)
|
1996-08-27 |
2000-05-16 |
Fusion Medical Technologies, Inc. |
Fragmented polymeric compositions and methods for their use
|
US5816259A
(en)
|
1997-01-13 |
1998-10-06 |
Rose; Samuel |
Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
|
US20020099003A1
(en)
|
1997-10-28 |
2002-07-25 |
Wilson Leland F. |
Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
JP2002507437A
(ja)
|
1998-02-27 |
2002-03-12 |
バイオエラスチックス・リサーチ・リミテッド |
組織の増強及び回復のための注射可能インプラント
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
FR2776520B1
(fr)
|
1998-03-25 |
2000-05-05 |
Sod Conseils Rech Applic |
Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
|
US6153655A
(en)
|
1998-04-17 |
2000-11-28 |
Enzon, Inc. |
Terminally-branched polymeric linkers and polymeric conjugates containing the same
|
US20020151458A1
(en)
|
1998-04-17 |
2002-10-17 |
Perez Gomariz Rosa Maria |
Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists
|
ES2138561B1
(es)
|
1998-04-17 |
2000-07-01 |
Univ Madrid Complutense |
Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
|
US6200598B1
(en)
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
US6406921B1
(en)
|
1998-07-14 |
2002-06-18 |
Zyomyx, Incorporated |
Protein arrays for high-throughput screening
|
WO2000056774A1
(en)
|
1999-03-19 |
2000-09-28 |
Duke University |
Methods of using bioelastomers
|
US20090175821A1
(en)
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
JP2004500906A
(ja)
|
1999-11-12 |
2004-01-15 |
ルーベン, レオ |
電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド
|
US6235264B1
(en)
|
1999-12-01 |
2001-05-22 |
General Electric Company |
Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
|
JP2001161363A
(ja)
|
1999-12-03 |
2001-06-19 |
Hisamitsu Pharmaceut Co Inc |
新規な小胞体局在タンパク質およびそれを含む糖タンパク質異常症治療薬、並びに該タンパク質をコードするdnaおよびそれを含む糖タンパク質異常症治療のための遺伝子治療薬。
|
US6593394B1
(en)
|
2000-01-03 |
2003-07-15 |
Prosperous Kingdom Limited |
Bioactive and osteoporotic bone cement
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
WO2001060863A1
(en)
|
2000-02-18 |
2001-08-23 |
Dabur Research Foundation |
Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
|
AU2000265051A1
(en)
|
2000-02-18 |
2001-08-27 |
Dabur Research Foundation |
Vasoactive intestinal peptide analogs
|
US20050255554A1
(en)
|
2000-03-20 |
2005-11-17 |
Ashutosh Chilkoti |
Fusion peptides isolatable by phase transition
|
US6852834B2
(en)
|
2000-03-20 |
2005-02-08 |
Ashutosh Chilkoti |
Fusion peptides isolatable by phase transition
|
ATE346093T1
(de)
|
2000-06-16 |
2006-12-15 |
Lilly Co Eli |
Analoge des glucagon ähnlichen peptid-1
|
WO2002000149A1
(en)
|
2000-06-23 |
2002-01-03 |
Drexel University |
Polymeric, fiber matrix delivery systems for bioactive compounds
|
EP1337557A2
(en)
*
|
2000-11-28 |
2003-08-27 |
Mondobiotech SA |
Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
|
EA005584B1
(ru)
|
2000-12-07 |
2005-04-28 |
Эли Лилли Энд Компани |
Слитые белки glp-1
|
EP1390061A2
(en)
|
2000-12-13 |
2004-02-25 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
US7144863B2
(en)
|
2001-06-01 |
2006-12-05 |
Eli Lilly And Company |
GLP-1 formulations with protracted time action
|
WO2003015615A2
(en)
|
2001-08-15 |
2003-02-27 |
Brown University Research Foundation |
Treatment of muscular dystrophies and related disorders
|
CA2458371A1
(en)
|
2001-08-23 |
2003-03-06 |
Eli Lilly And Company |
Glucagon-like peptide-1 analogs
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
ATE425762T1
(de)
|
2001-11-06 |
2009-04-15 |
Senju Pharma Co |
Mittel zur behandlung von augentrockenheit und damit zusammenhangenden erkrankungen
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2003103702A1
(en)
|
2002-06-10 |
2003-12-18 |
Mondobiotech Laboratories Anstalt |
Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
|
KR20050067439A
(ko)
|
2002-11-27 |
2005-07-01 |
이토햄 가부시키가이샤 |
펩티드 및 이를 포함하는 의약조성물
|
US20040234609A1
(en)
|
2003-05-14 |
2004-11-25 |
Collier Katherine D. |
Repeat sequence protein polymer active agent congjugates, methods and uses
|
PL1633391T3
(pl)
|
2003-06-03 |
2012-03-30 |
Novo Nordisk As |
Stabilizowane farmaceutycznie kompozycje peptydowe
|
JP2007513053A
(ja)
|
2003-07-14 |
2007-05-24 |
モンドバイオテック ラボラトリーズ アンシュタルト |
間質性肺感染症治療用の生物学的活性を有する血管作用性小腸ペプチドなる物質
|
WO2005014030A1
(en)
|
2003-07-24 |
2005-02-17 |
Lutz-Henning Block |
Method for treating lung diseases associated with ventilation-perfusion mismatches
|
US7928059B2
(en)
|
2004-02-24 |
2011-04-19 |
Wisconsin Alumni Research Foundation |
Use of neuropeptides for traumatic cartilage injury
|
US7776815B2
(en)
|
2004-02-24 |
2010-08-17 |
Wisconsin Alumni Research Foundation |
Use of neuropeptides for ligament healing
|
US20050203009A1
(en)
|
2004-03-12 |
2005-09-15 |
Bayer Pharmaceuticals Corporation |
VPAC1 selective antagonists and their pharmacological methods of use
|
JP2007530697A
(ja)
|
2004-03-29 |
2007-11-01 |
ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ |
両親媒性グリコペプチド
|
DE602005005476T2
(de)
|
2004-05-21 |
2009-03-05 |
Eli Lilly And Co., Indianapolis |
Selektive peptidische agonisten des vpac2-rezeptors
|
AU2005251386B8
(en)
|
2004-06-11 |
2010-10-14 |
Vectus Biosystems Pty Limited |
Compositions and methods for treatment of cardiovascular disease
|
CN101001639A
(zh)
|
2004-06-12 |
2007-07-18 |
拜尔药品公司 |
血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法
|
US20080085860A1
(en)
|
2004-08-18 |
2008-04-10 |
Eli Lilly And Company |
Selective Vpac2 Receptor Peptide Agonists
|
EP1781692A2
(en)
|
2004-08-18 |
2007-05-09 |
Eli Lilly And Company |
Selective vpac2 receptor peptide agonists
|
AU2005294125A1
(en)
|
2004-10-08 |
2006-04-20 |
Transition Therapeutics Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
US20080312156A1
(en)
|
2005-01-18 |
2008-12-18 |
Duke University |
In-Situ Crosslinkable Elastin-Like Polypeptides for Defect Filling in Cartilaginous Tissue Repair
|
US7723472B2
(en)
|
2005-02-28 |
2010-05-25 |
The Regents Of The University Of California |
Extracellular matrix binding chimeric proteins and methods of use thereof
|
EP1896072A4
(en)
|
2005-06-24 |
2013-01-09 |
Univ Duke |
SYSTEM FOR DIRECT HEALTH MANAGEMENT BASED ON HEAT-CONTROLLED BIOPOLYMERS
|
BRPI0617740A2
(pt)
|
2005-10-26 |
2011-08-02 |
Lilly Co Eli |
agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas
|
ATE458000T1
(de)
|
2005-11-18 |
2010-03-15 |
Dabur Pharma Ltd |
Zielgerichtete fusionsproteine für die krebstherapie
|
CN103450345B
(zh)
|
2005-12-09 |
2016-04-20 |
伟克特斯生物系统有限公司 |
Vip片段和应用方法
|
WO2007073486A2
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US7709227B2
(en)
|
2006-01-04 |
2010-05-04 |
Phasebio Pharmaceuticals, Inc. |
Multimeric ELP fusion constructs
|
US8367626B2
(en)
|
2006-05-12 |
2013-02-05 |
Wisconsin Alumni Research Foundation |
Elastin-like polymer delivery vehicles
|
WO2008030968A2
(en)
|
2006-09-06 |
2008-03-13 |
Phase Bioscience, Inc. |
Fusion peptide therapeutic compositions
|
ATE525394T1
(de)
|
2007-05-21 |
2011-10-15 |
Res Internat Sarl |
Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung
|
WO2009023270A2
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
US20110207673A1
(en)
|
2007-11-20 |
2011-08-25 |
Ashutosh Chilkoti |
Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
|
WO2009135184A2
(en)
|
2008-05-01 |
2009-11-05 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating and/or preventing cardiomyopathies by erk or jnk inhibition
|
EP4074327A1
(en)
|
2008-06-27 |
2022-10-19 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
WO2010006703A1
(en)
|
2008-07-15 |
2010-01-21 |
Bayer Schering Pharma Aktiengesellschaft |
G-protein coupled receptor 30 (gpr30) knockout mice as a model for cardiovascular diseases
|
US9333235B2
(en)
|
2008-10-22 |
2016-05-10 |
Trustees Of Dartmouth College |
Combination therapy and kit for the prevention and treatment of cystic fibrosis
|
CN102227430A
(zh)
|
2008-10-23 |
2011-10-26 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜传导调节因子的调节剂
|
US20110288001A1
(en)
|
2008-12-18 |
2011-11-24 |
Homayoun Sadeghi |
Biologically active proteins activatable by peptidase
|
MX366935B
(es)
|
2009-08-14 |
2019-07-31 |
Phasebio Pharmaceuticals Inc |
Peptidos intestinales vasoactivos modificados.
|
WO2011054001A2
(en)
|
2009-11-02 |
2011-05-05 |
The Administrators Of The Tulane |
Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
|
EP2552939A1
(en)
|
2010-04-02 |
2013-02-06 |
The Regents of the University of Michigan |
Rfamide-related peptides and methods thereof
|
CN103260647A
(zh)
|
2010-11-30 |
2013-08-21 |
伦敦健康科学中心研究公司 |
用于治疗心脏病的egfr拮抗剂
|
WO2012108379A1
(ja)
|
2011-02-07 |
2012-08-16 |
持田製薬株式会社 |
拡張性うっ血性心不全治療剤
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
CA2873553C
(en)
|
2011-06-06 |
2020-01-28 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
EP4295858A1
(en)
|
2011-08-24 |
2023-12-27 |
ImmunoForge Co., Ltd. |
Formulations of active agents for sustained release
|
SG11201402661TA
(en)
|
2011-11-28 |
2014-08-28 |
Phasebio Pharmaceuticals Inc |
Therapeutic agents comprising insulin amino acid sequences
|
ES2656321T3
(es)
|
2012-05-17 |
2018-02-26 |
I.E.R.F.C. European Institute For Cystic Fibrosis Research |
Terapia combinada para fibrosis quística
|
WO2013177428A1
(en)
|
2012-05-23 |
2013-11-28 |
Valerion Therapeutics, Inc. |
Methods for increasing muscle contractility
|
US10159741B2
(en)
|
2012-05-25 |
2018-12-25 |
National Cheng Kung University |
Methods and compositions comprising hyaluronan for enhancing bone marrow cell therapy
|
WO2014081849A1
(en)
|
2012-11-20 |
2014-05-30 |
Phasebio Pharmaceuticals, Inc. |
Formulations of active agents for sustained release
|
CN105025919A
(zh)
|
2013-01-15 |
2015-11-04 |
费斯生物制药公司 |
用于血糖控制的治疗剂、组合物和方法
|
EP3139949B1
(en)
|
2014-05-08 |
2020-07-29 |
Phasebio Pharmaceuticals, Inc. |
Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
|
CA2967394A1
(en)
|
2014-11-21 |
2016-05-26 |
Phasebio Pharmaceuticals, Inc. |
Elp fusion proteins for controlled and sustained release
|
AU2016219513B2
(en)
|
2015-02-09 |
2021-09-30 |
Immunoforge Co., Ltd. |
Methods and compositions for treating muscle disease and disorders
|